COMBINATION OF A RTK INHIBITOR WITH AN ANTI ESTROGEN AND USE THEREOF FOR THE TREATMENT OF CANCER

摘要

A pharmaceutical combination comprising (a) a RTK inhibitor selected from the group consisting of compounds of Formula I or a tautomer thereof compounds of Formula II or a tautomer thereof compounds of Formula III or a tautomer thereof a pharmaceutically acceptable salt of the compound a pharmaceutically acceptable salt of the tautomer or a mixture thereof; and (b) one or more anti estrogen compounds or a pharmaceutically acceptable salt thereof; such as tamoxifen toremifene fulvestrant raloxifene or raloxifene hydrochloride; the uses of such combination in the treatment or prevention of proliferative diseases; and methods of treating a subject suffering from a proliferative disease; and methods of treating a subject suffering from a proliferative disease comprising administering a therapeutically effective amount of such combination.